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g.2012.0Abstract Mitochondrial respiratory chain disorders (RCD) are a group of genetically and clini-
cally heterogeneous diseases, caused due to defects of the respiratory chain. This study aimed to
investigate the presence of common mtDNA point mutations in tRNALeu (UUR), tRNALys,
MT-ATPase 6, MT-ND4, MT-ND1, MT-ND6 genes in eight Egyptian patients suspected to have
mtDNA disease and optic atrophy.
PCR-RFLP analysis was done for the detection of 3243A > G, 3271T > C, 8344A > G, and
8993T > G/C mtDNA point mutations. DNA direct sequencing was pursued for the detection
of 11778G > A, 3460G > A and 14484T > C mtDNA point mutations. No point mutation of
3243A > G, 3271T > C, 8344A > G, and 8993T > G/C was detected in our group of patients.
Four mtDNA polymorphisms in MT-ND1 and MT-ND4 genes (11467A > G, 11719G > A,
3348A > G and 3357G > A) were detected in three patients.
Mitochondrial disorders are caused by a variety of genetic and racial factors, which differ among
populations. The negative results of this study indicate that the chosenmutationsmight not be speciﬁc
in Egyptians. Another explanation might be due to the low heteroplasmic levels of the mtDNAmuta-
tion. A registry for the different mtDNA mutations in Egyptian patients is highly recommended.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.rtment of Medical Molecular
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8.0021. Introduction
Mitochondrial respiratory chain diseases (RCDs) are a hetero-
geneous group of inherited disorders characterized by im-
paired energy metabolism due to oxidative phosphorylation
(OXPHOS) dysfunction [1,2]. Neurons and myocytes are
highly dependent on ATP produced by mitochondria, so these
tissues are primarily affected [3,4]. A reported minimum birth
prevalence of mitochondrial RCDs was 1/5000 [1]. Studies inier B.V. All rights reserved.
38 G.M.M. Al-Ettribi et al.adults and/or children suggest a prevalence approaching 1/
7600 in Australia [5] and 1/21,000 in Sweden [6]. Mitochon-
drial RCDs can be caused by either mitochondrial DNA
(mtDNA) or nuclear DNA (nDNA) mutations. Mutations in
the mitochondrial genome could be either large-scale rear-
rangements or point mutations [7,8].
A number of ‘classical’ syndromes have been described that
are often, but not always, associated with a particular geno-
type. They include mitochondrial myopathy, encephalopathy,
lactic acidosis and stroke-like episodes (MELAS), myoclonic
epilepsy and ragged red ﬁbers (MERRF), maternal inherited
Leigh’s syndrome (MILS), neurogenic muscle weakness, atax-
ia, and retinitis pigmentosa (NARP), Leber’s hereditary optic
neuropathy (LHON), and progressive external ophthalomo-
plegia (PEO). However, a substantial group of patients, partic-
ularly children, do not fulﬁll the clinical criteria for a particular
syndrome and may have symptoms or signs that overlap one
or more clinical syndromes [8,9].
There is a number of recurrent mtDNA point mutations,
including the 3243A > G transition in the mitochondrial trans-
fer RNA Leucine1 gene (tRNALeu (UUR); OMIM#590050),
which is the most commonmtDNA point mutation. It accounts
for more than 85% of patients with MELAS and for a large
number of PEO patients that do not have large-scale deletions.
The less common 3271T > C mutation in the same gene was
found in about 10% of MELAS patients [10,11]. The point
mutation 8344A > G in the tRNALys gene (OMIM#590060)
has been found in >85% MERRF patients [12]. The
8993T > G/C mutations in the mitochondrial ATP synthase
subunit 6 gene (MT-ATPase 6; OMIM#516060) are found in
about 10–30%of individuals withMILS [13–15], while the same
mutations account for >50% in NARP patients with elevated
blood lactate concentration [13,16]. Several point mutations in
protein coding genes have been described in LHON patients,
speciﬁcally the transition 11778G > A in the mitochondrial
NADH reductase subunit 4 gene (MT-ND4; OMIM#516003)
that account for approximately 50%of all cases. The three point
mutations 11778G > A, 3460G > A in the MT-ND1 gene
(OMIM#516000) and 14484T > C in the MT-ND6
gene (OMIM#516006) account for 90–95% of LHON cases
[17,18].
Obtaining a deﬁnitive and speciﬁc molecular diagnosis for a
patient with clinically suspected mtDNA diseases allows more
speciﬁc medical management, accurate genetic counseling, pre-
natal diagnosis, and overcomes the ambiguities often seen with
biochemical analysis, histological, and enzymatic evaluations
[19]. In this study we aimed to investigate the presence of the
most common mtDNA point mutations (3243A >G,
3271T > C, 8344A > G, 8993T > G/C, 11778G > A,
3460G > A and 14484T > C) in Egyptian patients who are
suspected to have mtDNA diseases and optic atrophy.2. Subjects and investigations
2.1. Subjects
The study included eight Egyptian patients (four males and
four females) with clinical suspicion of mitochondrial disease
and optic atrophy. The purpose and the extent of the study
were explained to the parents, and consent forms were ob-
tained and approved by the National Research Center(NRC) Ethics Research Committee. Patients were clinically
examined to detect any malformation and anomalies. Pedigree
was constructed. Mitochondrial diseases were diagnosed
depending on a high index of suspicion based on neurologic,
muscular, ophthalmologic, hearing loss, neurophysiological
impairment and increase in lactate and pyruvate plasma levels.
Since this is mainly based on a diagnosis of exclusion, all other
causes were considered and ruled out. The following investiga-
tions were done for all patients:
*Neurophysiological investigations:
Electroencephalogram (EEG)
Electromyelogram (EMG)
Nerve conduction studies (NCS)
Complete eye evaluation including electroretinogram
(ERG) and visual-evoked potential (VEP)
Hearing test
Magnetic resonance imaging (MRI)
Magnetic resonance spectroscopy (MRS)
*Pathological examination:
Muscle biopsy was stained by the modiﬁed Gomori tri-
chrome stain [20]
*Biochemical assessments:
Plasma lactate (9.0–16.0 mg/dL) [21]
Plasma pyruvate (0.3–0.7 mg/dL) [22]
3. Methods
3.1. DNA extraction
Five ml venous blood was used for DNA extraction by the
salting-out procedure of [23].
3.2. PCR ampliﬁcation
Seven uniplex PCR ampliﬁcations were performed using the
following primers for the detection of the seven common re-
ported mutations.
(1) Mutation 3243A > G [24]
F: 50- CCT CCC TGT ACG AAA GGA C -30
R: 50- GCG ATT AGA ATG GGT ACA ATG-30
(2) Mutation 3271T > C [25]
F: 50- AGG ACA AGA GAA ATA AGG C -30
R: 30- AAT TCC AGT CTC CAA GTT AAG GAG AAG
AAT -50
(3) Mutation 8344A > G [26]
F: 50- CCC CCA TTA TTC CTA GAA CCA GGC G -30
R: 50- GGG GCA TTT CAC TGT AAA GAG GTG TGG
G -30
(4) Mutation: 8993T > G/C [27]
F: 50- CCG ACT AAT CAC CAC CCA AC -30
R: 30- TTC GGA GAT GGA CGT GCT GT -50
(5) Mutation: 11778G > A [28]
F: 50- CCC ATC GCT GGG TCA ATA GT -30
R: 30- G GT GCA AGA GGA CTA GTT TA -50
(6) Mutation: 3460G > A [29]
F: 50- CAG TCA GAG GTT CAA TTC CTC -30
R: 30- ATG ATA CTT GGG GGG AGG GGT -50
(7) Mutation: 14484T > C [30]
Figure 1 Pedigree of patient 2 showing maternal inheritance.
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R: 30- ATT TGG GTA TAT TGG AGG GGG TTT -50
3.3. Restriction enzyme digestion
Ampliﬁed PCR products containing suspected mutations,
3243A> G, 3271T> C, 8344A> G and 8993T> G/C were
digested using four restriction endonucleases HaeIII, AﬂII, Ba-
nII and HpaII (Fermentas, European union), respectively. Di-
gested PCR products were analyzed by polyacrylamide gel
electrophoresis.
3.4. DNA sequencing
Ampliﬁed PCR products containing suspected mutations
11778G > A, 3460G > A and 14484T > C mtDNA were
puriﬁed using the QIAquickT (Qiagen, Germany) PCR Puri-
ﬁcation Kit for further analysis by DNA sequencing. Cycle
sequencing reactions were performed in 20 ll total volumes
containing 8 ll ABI PRISM BigDye Terminator v3. 1
Ready Reaction Mix, Applied Biosystems ABI 310 DNA Se-
quencer using 310 Data Collection Software version 3.1.0.
Sequencing products were analyzed using DNA Sequencing
Analysis Software version 5.4. Sequencing results were evalu-
ated both manually and automatically with the Sequence
Navigator.
4. Results
The study included eight patients with mitochondrial disorder
and optic atrophy; four were females and four were males. Pa-Figure 2 Axial T2 of patient 2 showing bilateral high signal of lentifor
mild cortical atrophic changes.tients’ ages of onset ranged from 2 months to 3 years (mean
age was 1 year and 3 months). Patient 1 (P1) had a maternal
relative with psychiatric disease, P2 had a affected mother
and a similarly affected sib, (Fig. 1). P4 had a family history
of a similarly affected sib, P3 had two sibs manifested with sei-
zure and died before the age of 1 year, and P6 had a family his-
tory of three neonatal deaths by congenital heart disease. All
patients in the study presented with hypotonia and optic atro-
phy. Seizures were present in six cases and mental retardation
in two cases. Dystonia was found in one case, microcephaly in
one case, moderate sensorineural hearing loss in one case, nys-
tagmus in one case and papilledema and ptosis in another.
Pathological examination of muscle biopsy showed ragged
red ﬁbers (RRF) in one case. Neurophysiological investiga-
tions: EMG revealed myopathy in all cases; MRI brain showed
cortical atrophy, white matter demyelination and/or basal gan-
glia degeneration. NCS showed demyelinating neuropathy in
peripheral nerves in four cases. The EEG showed epileptogenic
dysfunction in three cases. MRS showed a high lactate peak in
two cases, (Figs. 2–4) Table 1.m nucleus (mainly globus pallidus), deep while matter changes and
Figure 3 MR spectroscopy for patient 6 showing high signal of
lentiform nucleus and high lactate peak indicating mitochondrial
disorders.
40 G.M.M. Al-Ettribi et al.PCR-RFLP analysis for detection of four of the common
mitochondrial mutations was negative in all patients (Figs. 5–
8). In all cases, only a band corresponding in size to that of the
fragment containing the normal nucleotide was observed: a
196 bp band for the 2343A digested fragment (Fig. 5), a
172 bp band for the 3271T fragment (Fig. 6), two bands (299
and 78 bp) for the 8344A digested fragment (Fig. 7), and a
554 bp band for the 8993T fragment (Fig. 8).
DNA sequencing revealed the absence of mitochondrial
mutations 11778G> A, 3460G> A and 14484T> C in all
patients. Four mitochondrial variants in MT-ND1 and MT-
ND4 genes were found in patients 3, 4, and 8. Gene loci, codon
changes, amino acid changes and status of the four variants
11467A >G, 11719G > A, 3348A >G and 3357G > A are
summarized in Table 2.
5. Discussion
Diagnosing mitochondrial RCDs remains a major challenge to
the clinician due to their varied age at onset, clinicalFigure 4 Axial T2 for patient 6 showing deep wpresentations and their genetic heterogeneity [8,19]. Thus,
mitochondrial diseases may present with ‘‘any symptom in
any organ at any age’’ [31]. The age of onset in patients of pa-
tients included in this study ranged between 2 months and
3 years, a range that was reported with several mitochondrial
diseases including MELAS (<2 to >20 years in 70% of
cases [32]), MERRF (childhood age [12]), MILS (typically 3–
12 months, later onset >1 year or in adulthood occurs in up
to 25% of patients [33]) and NARP (early childhood [13]).
The peak age of onset in LHON varies between the second
and the third decades of life [17]. However, visual deterioration
can occur at any time during the ﬁrst to the seventh decade of
life and LHON should be part of the differential diagnosis of
all cases of bilateral, simultaneous or sequential optic neurop-
athy, irrespective of age and especially in male patients [34,35].
Taking a family history is difﬁcult when we consider the rel-
atively non-speciﬁc features of mitochondrial diseases. Patients
with unaffected maternal relatives may be due to variation in
the expression of the disease or in the presence of low levels
of heteroplasmic mutations [8,36]. Also, the clinical variability
among siblings that was found in patients 3 and 6 is one of the
most remarkable features of mitochondrial disease caused by
mtDNA defects. This is thought to reﬂect the mitochondrial
‘‘genetic bottleneck’’. However, this difference in the transmit-
ted mutation load does not explain why one sibling might pres-
ent with neurological disease while another might develop
heart failure. Clearly additional factors must come into play
[37].
Seven out of the eight patients included in this study
showed multisystem involvement (brain, eye, and muscles)
reﬂecting, in part, the dependence on energy derived from oxi-
dative phosphorylation in a wide variety of tissues; a feature
that is a hallmark of mitochondrial diseases and may be the
initial indication to the correct diagnosis [9,19]. Our patients
did not fulﬁll the clinical criteria of any speciﬁc classical syn-
drome. However, they manifested with the common symptoms
of mitochondrial diseases that include seizures, stroke-like epi-
sodes, neuropathy, ptosis, dystonia and unexplained hypoto-
nia in newborn, infant, or young child [9,31] in conjunction
with other symptoms such as hearing loss and visualhite matter changes and mild cortical atrophy.
Table 1 Clinical and laboratory data of the eight patients with mitochondrial disorder.
Patient number/
gender
Age of onset Clinical symptoms Eye manifestation Blood lactate
(9.0–16.0 mg/
dL)/pyruvate
(0.3–0.7 mg/dL)
Investigat ns
1/M 1 yr Hypotonia hyporeﬂexia dystonia Optic atrophy 32/1.4 EMG: m pathy. MRI: white matter demyelination, cerebral and
cerebellar trophy and basal ganglia degeneration
2/ F 2 yr Severe hypotonia seizure stroke Optic atrophy 33/2 EMG: m pathy. NCS: demyelinating neuropathy. MRI: white
matter ch nges and mild cortical atrophic changes
3/F 2 mo Hypotonia brisk reﬂexes seizures
microcephaly
Optic atrophy 22/3.2 EEG: bila eral temporoparietal epileptogenic dysfunction. EMG:
myopathy MRI: simpliﬁed gyral pattern anteriorly with atrophic
changes, pogenesis of corpus callosum, white matter
demyelina ion
4/M 4 mo Hypotonia brisk reﬂexes ankle clouns
seizures sensorineural hearing loss
(SNHL)
Optic atrophy 34/2.2 EMG: m pathy. NCS: demyelinating neuropathy in peripheral
nerves. M scle biopsy: ragged red ﬁbers. MRI: cortical atrophic
changes a d basal ganglia degeneration
5/M 6 mo Hypotonia seizures Optic atrophy 33.5/3.4 EMG: m pathy. MRI: basal ganglia degeneration and white
matter de yelination
6/ F 1 yr Hypotonia hyporeﬂexia seizures Optic atrophy
papilledema ptosis
35/2 EEG: bila eral focal epileptogenic. EMG: myopathy. NCS:
demyelina ing neuropathy in peripheral nerves. MRI: white matter
changes a d mild cortical atrophy. MRS: high lactate peak
7/F 2 yr Mental retardation hypotonia Optic atrophy 25/1 EMG: m pathy. MRI: white matter demyelination and basal
ganglia d eneration. MRS: high lactate peak
8/M 3 yr Mental retardation hypotonia
seizures
Nystagmus optic
atrophy
32/2 EMG: m pathy, EEG: epileptogenic dysfunction, NCS:
demyelina ing neuropathy in peripheral nerves. MRI: Cortical
atrophic anges
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Figure 5 8% Polyacrylamide gel electrophoretic analysis of HaeIII digestion of the PCR product for detection of mutation 3243A > G.
Fragments containing normal 3243A nucleotide have two enzyme recognition sites that cleave it into three bands (169, 37 and 32 bp). The
3243G mutated nucleotide introduces another enzyme recognition site into the ampliﬁed fragments that are digested producing 97, 72, 37
and 32 bp bands. Lane (1): undigested PCR product (238 bp). Lanes (2–8): digested PCR products from seven different patients showing
digestion pattern of normal fragments only. M1: 50 bp DNA ladder; its fragment lengths are demonstrated left to the ﬁgure (in green).
M2: ØX174 HaeIII molecular weight marker; its fragment lengths are demonstrated left to the ﬁgure (in red). The dot marks represent the
reference bands that correspond to the analyzed fragments.
Figure 6 8% Polyacrylamide gel electrophoretic analysis of AﬂII digestion of the PCR product for detection of mutation 3271T > C.
Fragments containing normal 3271T nucleotide have no enzyme recognition site. The 3271C mutated nucleotide introduces one enzyme
recognition site into the ampliﬁed fragments that are digested producing 142 and 30 bp bands. Lanes (1–2): undigested PCR products.
Lanes (3–8): digested PCR products from 6 different patients showing digestion pattern of normal fragments only. M1: 50 bp DNA
ladder; its fragment lengths are demonstrated left to the ﬁgure (in green). M2: ØX174 HaeIII molecular weight marker; its fragment
lengths are demonstrated left to the ﬁgure (in red). The dot marks represent the reference bands that correspond to the analyzed
fragments.
42 G.M.M. Al-Ettribi et al.impairment. This coincides with the ﬁndings of McFarland
and Turnbull [9] who reported similar mitochondrial cases
with atypical phenotype.
All of our patients manifested with optic atrophy and hypo-
tonia; two red ﬂag ﬁndings in mitochondrial diseases [31].
Although, optic atrophy is the primary and generally the only
clinical manifestation in most LHON pedigrees [38], it is man-
ifested also as a secondary feature, overshadowed by other
more prominent neurological and ocular manifestations, in
several mitochondrial diseases including MELAS, MERRF,
CPEO, KSS, MILS, and mitochondrial neuro-gastrointestinal
encephalomyopathy (MNGIE) [17,39]. Several studies of pa-
tients with LS showed hypotonia as a feature of their disease
[40–43]. Hypotonia, dystonia, muscle weakness, hypo orhyperreﬂexia, seizures, mental retardation, movement disor-
ders, peripheral neuropathy, eye movement disorders and op-
tic atrophy are all abnormalities due to focal and necrotizing
lesions characterizing LS [13,15,44]. Optic atrophy, hypotonia
and seizures alone or in association with brisk reﬂexes were
found in two of our patients whose ages of onset were 2 and
6 months. The patient with brisk reﬂexes also showed micro-
cephaly that is a non-speciﬁc feature that increases the likeli-
hood of a mitochondrial disorder [31] and was found in
association with brainstem dysfunction and growth retarda-
tion in LS patients [45].
Seizures were also found in four other patients included in
this study. In one of them, seizures manifested at an age of
2 years, the patient had experienced a stroke attack and had
Figure 7 10% Polyacrylamide gel electrophoretic analysis of BanII digestion of the PCR product for detection of mutation 8344A > G.
Fragments containing normal 8344A nucleotide have two enzyme recognition sites that cleave it into three bands (299, 78 and 41 bp). The
8334G mutated nucleotide introduces another enzyme recognition site into the ampliﬁed fragments that are digested producing 299, 52, 41
and 26 bp bands. Lanes (1–2): undigested PCR product (418 bp). Lanes (3–8): digested PCR products from ﬁve different patients showing
digestion pattern of normal fragments only. M1: 50 bp DNA ladder; its fragment lengths are demonstrated left to the ﬁgure (in green).
M2: ØX174 HaeIII molecular weight marker; its fragment lengths are demonstrated left to the ﬁgure (in red). The dot marks represent the
reference bands that correspond to the analyzed fragments.
Figure 8 8% Polyacrylamide gel electrophoretic analysis of HpaII digestion of the PCR product for detection of mutation 8993T > C.
Fragments containing normal 8993T nucleotide have no enzyme recognition site. The 8993C mutated nucleotide introduces one enzyme
recognition site into the ampliﬁed fragments that are digested producing 347 and 207 bp bands. Lanes (1–2): undigested PCR product
(554 bp). Lanes (3–7): digested PCR products from 5 different patients showing digestion pattern of normal fragments only. M1: 50 bp
DNA ladder; its fragment lengths are demonstrated left to the ﬁgure (in green). M2: ØX174 HaeIII molecular weight marker; its fragment
lengths are demonstrated left to the ﬁgure (in red). The dot marks represent the reference bands that correspond to the analyzed
fragments.
Table 2 mtDNA variants found in the eight Egyptian patients as compared to the human mtDNA revised Cambridge reference
sequence.
Patient number Nucleotide number and substitution Codon Change Locus Amino acid change Status
4 11467A> G TTA> TTG MT-ND4 L236L Homoplasmic
4 and 8 11719G> A GGG>GGA MT-ND4 G320G Homoplasmic
4 3348A> G CTA> CTG MT-ND1 L14L Homoplasmic
3 3357G> A ATG> ATA MT-ND1 M17M Homoplasmic
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44 G.M.M. Al-Ettribi et al.a family history of an affected brother who showed similar
symptoms. This family was suspected to suffer from MELAS
syndrome. Thus, encephalopathy characterized by seizures,
dementia or both and stroke-like episode before the age of
40 years are two of three almost invariant criteria for diagnos-
ing MELAS [32]. Seizures were found in 96% of MELAS pa-
tients while 99% had stroke-like episodes in the study of
Hirano and Pavlakis [46].
The three other patients with seizures had features of hear-
ing loss and RRF on muscle biopsy, ptosis, papilledema and
hyporeﬂexia, nystagmus and mental retardation. Hearing loss
is a common disabling feature of mitochondrial disease with a
variable age of onset. It frequently occurs in families harboring
the 3243A > G mutation [47], other mtRNA gene mutations
[48–51] and in LHON, Kearns Sayre, CPEO [52], and with
non-classical mitochondrial diseases [53]. RRF on muscle
biopsy demonstrating abnormal subsarcolemmal accumula-
tions of mitochondria is suggestive of mitochondrial disease.
Thus, the presence of >2% RRFs on skeletal muscle biopsy
is taken as one of the criteria for the diagnosis of mitochon-
drial disorders [54]. Mental retardation and seizures were de-
tected in 52.6% of Egyptian patients with non classical
mitochondrial diseases [53], in a MELAS patient with hypoto-
nia, convulsion and right hemiparesis [55]. While mental retar-
dation alone was found in 59% of LS patients [56] and in
MERRF patients [57]. Nystagmus is one of the clinical fea-
tures of OXPHOS defects presenting in the neonatal period
[58], commonly associated with LS [9,40] and was found in
LHON patients [59]. Ptosis was reported in probands with
MELAS/MERRF overlap disease [60], LS [56,61] and non-
classical mitochondrial disease [53,62].
All of our patients had high blood lactate and pyruvate lev-
els. Two patients also showed high lactate peak on MRS. De-
spite their lack of speciﬁcity, an elevated plasma lactate or
pyruvate level can be an important marker of mitochondrial
disease [31].
Demyelination around occipital horns found in patient 6
was reported in MELAS patients [32]. Brain atrophy and basal
ganglia degeneration found in patients 1, 2 and 4 are often seen
in MERRF patients [63]. Basal ganglia with prominent cere-
bellar involvement found in patient 1 have been reported to
be consistent with Leigh syndrome [64]. Another study by
El-Bassyouni et al. [53] found cerebral white matter affection
and cerebellar atrophy in 12/19 patients (63.2%) and basal
ganglia calciﬁcation in 2/19 patients (10.5%) with mitochon-
drial disorders.
One of our patients showed abnormal subsarcolemmal
accumulations of mitochondria on skeletal muscle biopsy
stained with Gomori trichrome, a unique feature of mitochon-
drial disease described as the ‘RRF’. However, RRFs are
rarely seen in early childhood, when subsarcolemmal accumu-
lation of mitochondria may be mild or absent. Additionally,
abnormal accumulation of mitochondria may be absent in pa-
tients with proven mitochondrial disease such as LS and
NARP [9,13,19].
Molecular analysis in our patients did not reveal any of the
common mutations associated with mitochondrial respiratory
chain disorders. This might be due to the low level hetero-
plasmy of the mtDNA mutation in peripheral blood samples,
a situation reported by Haas et al. [2] to be responsible for false
negative results. The 3243A > G MELAS mutation can be
found in about 50% of the cases when blood samples are usedfor PCR-RFLP. This is thought to be the result of the rapidly
replicating ability of the blood cells, which will gradually elim-
inate the leukocytes with a higher mutation load [65]. 10–15%
of LHON patients have heteroplasmic mutations in different
tissues [38,66,67]. On the other hand, white blood cells or
any other tissue type can be used to test for the 8993T > G/
C mutations [13]; as they do not show any signiﬁcant variation
in mutation load among tissues [68].
Detecting the causative mutation is another challenge in
molecular diagnosis. Determining which one of dozens, if
not hundreds of genes spanning two genomes responsible for
mitochondrial dysfunction in a given patient is the challenge
[2]. MELAS was reported to be associated with many other
mutations concentrated on the mtRNALeu (UUR) gene, even
though there are more than thirty pathogenic mtDNA muta-
tions in other mtRNA or protein-coding genes seen with the
disease [10]. Mutations causing MERRF appear to be re-
stricted to tRNA gene [69]. However, single cases of other
non-tRNA mitochondrial point mutations, multiple mtDNA
deletions [70] or nuclear DNA mutation in the polymerase
gamma gene (POLG) have been described [71]. In LHON,
many mtDNA point mutations have been described, but each
account for only one or a few pedigrees worldwide. Most of-
ten, these other mutations involve genes encoding the ND1
and ND6 subunits of complex I as they are considered ‘‘muta-
tional hotspots’’ region for the disease [38] accounting for 50–
90% of LHON pedigrees in different ethnic groups [72].
Approximately 10%-20% of individuals with MILS have
mutations in other mitochondrial genes than MT-ATP6
[14,15,73].
DNA sequence analysis in order to detect mutations 11778
and 3460 in our patients showed the presence of 4 mitochon-
drial variants named 11467A > G, 11719G > A,
3348A > G and 3357G > A. Both 11467A >G and
11719G > A are silent polymorphisms located on the mito-
chondrial genome within the ND4 gene. They had been previ-
ously described in control individuals [74]. Two studies of
Kumar et al. [72] and Puomila et al. [75] reported that none
of the two variants fulﬁlled the criteria for a primary patho-
genic mtDNA mutation. The 11467A >G is a mitochondrial
SNP that belongs to ethnic-speciﬁc haplogroups K which
showed a signiﬁcantly higher association to altered brain pH
in patients suffering from psychiatric disorders [76]. Also, it
is reported as haplogroup U5 and U6 speciﬁc polymorphism
[77]. The 11719G > A polymorphism was reported in all T,
J, U, X, and K haplogroups [78]. Howell et al. [79] found
11719G > A in the matrilineal pedigree of the 14482 LHON
family. The 3348A > G and 3357G> A transitions are syn-
onymous mitochondrial SNPs located in the mitochondrial
ND1 gene [80]. The 3348A > G change characterizes the
U6a haplogroup that is one of the African mitochondrial
haplogroups [77,78].
In conclusion, establishing a speciﬁc diagnosis in a patient
with the suspected mitochondrial disease is a complex endea-
vor that requires the integration of clinical assessments, family
history, electrophysiologic investigations, biochemical testing,
histopathological examination, and molecular testing. Close
collaboration between primary clinicians, geneticists, patholo-
gists, other clinical specialists, and diagnostic laboratories with
expertise in mitochondrial biochemical and molecular testing is
critical to maximize the likelihood of obtaining a correct
diagnosis. Not ﬁnding the chosen common mutations in our
Molecular study of mitochondrial disorders in Egyptians 45study could be due to low heteroplasmic levels of the mtDNA
mutations in leukocytes or the presence of other mutations in
either of the two genomes. Screening for more mutations is rec-
ommended to reach a speciﬁc diagnosis.
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